Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139555
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-08-29
Brief Title:
Effects of AmlodipineBenazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Effects of AmlodipineBenazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Left ventricular hypertrophy LVH increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure compared to those without LVH Reduction of left ventricular mass LVM with antihypertensive agents is associated with improved clinical outcome This study will evaluate the effects of amlodipinebenazepril in reducing LVM in patients with high risk hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None